JP2020531521A5 - - Google Patents

Info

Publication number

JP2020531521A5

JP2020531521A5 JP2020511255A JP2020511255A JP2020531521A5 JP 2020531521 A5 JP2020531521 A5 JP 2020531521A5 JP 2020511255 A JP2020511255 A JP 2020511255A JP 2020511255 A JP2020511255 A JP 2020511255A JP 2020531521 A5 JP2020531521 A5 JP 2020531521A5

Authority

JP

Japan

Prior art keywords

seq

pharmaceutical composition

amino acid

concentration

acid sequence

Prior art date

2018-08-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims description 83
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 78
• 239000012634 fragment Substances 0.000 claims description 49
• 239000000203 mixture Substances 0.000 claims description 46
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 42
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 18
• 239000003963 antioxidant agent Substances 0.000 claims description 18
• 150000003573 thiols Chemical class 0.000 claims description 18
• 230000003078 antioxidant effect Effects 0.000 claims description 17
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 16
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 16
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 16
• 229920000053 polysorbate 80 Polymers 0.000 claims description 16
• 229940068968 polysorbate 80 Drugs 0.000 claims description 16
• 108010053070 Glutathione Disulfide Proteins 0.000 claims description 15
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 15
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 15
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 15
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 15
• YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims description 15
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 14
• 229930182817 methionine Natural products 0.000 claims description 14
• 239000001509 sodium citrate Substances 0.000 claims description 14
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 14
• 206010016654 Fibrosis Diseases 0.000 claims description 13
• 230000004761 fibrosis Effects 0.000 claims description 13
• 208000024891 symptom Diseases 0.000 claims description 10
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
• LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 8
• 235000018417 cysteine Nutrition 0.000 claims description 8
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 8
• 229960003067 cystine Drugs 0.000 claims description 8
• 208000009304 Acute Kidney Injury Diseases 0.000 claims description 7
• 206010069351 acute lung injury Diseases 0.000 claims description 7
• 208000033626 Renal failure acute Diseases 0.000 claims description 6
• 201000011040 acute kidney failure Diseases 0.000 claims description 6
• 238000009472 formulation Methods 0.000 claims description 6
• 208000005069 pulmonary fibrosis Diseases 0.000 claims description 6
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 4
• 239000000427 antigen Substances 0.000 claims description 4
• 102000036639 antigens Human genes 0.000 claims description 4
• 108091007433 antigens Proteins 0.000 claims description 4
• XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims description 4
• 229960004378 nintedanib Drugs 0.000 claims description 4
• 238000007920 subcutaneous administration Methods 0.000 claims description 4
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 3
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 3
• 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 3
• ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims description 3
• 229960003073 pirfenidone Drugs 0.000 claims description 3
• 229960003589 arginine hydrochloride Drugs 0.000 claims description 2
• 230000003442 weekly effect Effects 0.000 claims 2
• 238000000034 method Methods 0.000 description 35
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1